First analysis of the event-free survival of the GeparDuo-study: neoadjuvant doxorubicin / cyclophosphamide followed by docetaxel (AC-Doc) versus dose-dense doxorubicin and docetaxel (ADoc) in breast cancer

Authors
Publication date
20 March 2006
Publisher
German Medical Science; Düsseldorf, Köln

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    German Medical Science

    redirect
    oaioai:oai-gms.dimdi.de:GM06dkk15...
    Last time updated on 09/07/2019